• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endo Pharmaceutical Holdings

Endo Pharmaceutical Holdings

Endo International PLC ENDP 3 Star

Last Price$85.34Day Change (%)0.36%
Open Price$84.85Day Change ($)0.31
Day Range84.56–86.0552-Week Range57.14–96.58

As of Fri 5/22/2015 11:54:00 AM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. UPDATE: Etsy shares fall after results show surprise loss

    UPDATE: Etsy shares fall after results show surprise loss

  2. First Ever Peyronie's Disease (PD) Treatment Guidelines Support Use of XIAFLEX® in Appropriate Patients

    First Ever Peyronie's Disease (PD) Treatment Guidelines Support Use of XIAFLEX® in Appropriate Patients

  3. MARKET SNAPSHOT: S&P 500, Dow Close At All-time Highs

    MARKET SNAPSHOT: S&P 500, Dow Close At All-time Highs

  4. UPDATE: S&P 500, Dow close at all-time highs

    UPDATE: S&P 500, Dow close at all-time highs

  5. Endo Announces Updated XIAFLEX® Label with Recurrence and Retreatment Data in Patients with Dupuytren's Contracture

    Endo Announces Updated XIAFLEX® Label with Recurrence and Retreatment Data in Patients with Dupuytren's Contracture

  6. Endo Acquires Broad Portfolio of Branded and Generic Products, Expanding International Pharmaceuticals Business

    Endo Acquires Broad Portfolio of Branded and Generic Products, Expanding International Pharmaceuticals Business

  7. Endo Pharmaceuticals and BioDelivery Sciences Present Pivotal Data from Two Phase 3 Trials Demonstrating Safety and Efficacy of Buprenorphine HCl Buccal Film for the Management of Chronic Pain

    Endo Pharmaceuticals and BioDelivery Sciences Present Pivotal Data from Two Phase 3 Trials Demonstrating Safety and Efficacy of Buprenorphine HCl Buccal Film for the Management of Chronic Pain

  8. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  9. Health Care: 3 Picks in a More Expensive Sector

    Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

  10. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.